Tag
#HROW
-
2026
-
Samsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with Harrow
-
Harrow Announces Commercial Launch of BYOOVIZ® in the United States
-
HROW – 8-K
-
Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare
-
HROW – 8-K
-
Harrow to Present at William Blair’s 46th Annual Growth Stock Conference
-
HROW – 10-Q
-
Harrow Announces First Quarter 2026 Financial Results
-
HROW – 8-K
-
Harrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026
-
HROW – DEF 14A
-
HROW – DEFA14A
-
Harrow Announces the Issuance of J-Code for IOPIDINE® 1%
-
LogiCare3PL Selected as Distribution Partner by Harrow
-
HROW – 8-K
-
Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030
-
HROW – 8-K
-
Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030
-
Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth
-
HROW – 8-K
-
Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth
-
Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting
-
Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting
-
HROW – 8-K
-
Harrow to Present at Leerink Partner’s 2026 Global Healthcare Conference